The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m
The company expects the GMP approval from Saudi Food and Drug Authority (SFDA) to soon pave the way for marketing authorizations from the largest market in the GCC region
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
Spiro will be responsible for the overall strategy, implementation and growth of Lupin’s U.S. Generics business
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery
He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets
Proceeds from the proposed issue will be utilized to part finance Balaxi’s planned EU GMP-compliant manufacturing facility for Oral Solid Dosages and Liquid Injectables at TSIIC Pharma Formulations SEZ
The capital expansion program commenced in June 2022 and is expected to complete in 2024
Subscribe To Our Newsletter & Stay Updated
